These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTES. McBride JW; Boyd P; Dias N; Cameron D; Offord RE; Hartley O; Kett VL; Malcolm RK J Control Release; 2019 Mar; 298():1-11. PubMed ID: 30731150 [TBL] [Abstract][Full Text] [Related]
5. Characterisation of protein stability in rod-insert vaginal rings. Pattani A; Lowry D; Curran RM; McGrath S; Kett VL; Andrews GP; Malcolm RK Int J Pharm; 2012 Jul; 430(1-2):89-97. PubMed ID: 22486955 [TBL] [Abstract][Full Text] [Related]
6. Matrix and reservoir-type multipurpose vaginal rings for controlled release of dapivirine and levonorgestrel. Boyd P; Fetherston SM; McCoy CF; Major I; Murphy DJ; Kumar S; Holt J; Brimer A; Blanda W; Devlin B; Malcolm RK Int J Pharm; 2016 Sep; 511(1):619-629. PubMed ID: 27473275 [TBL] [Abstract][Full Text] [Related]
7. Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir. Murphy DJ; Desjardins D; Dereuddre-Bosquet N; Brochard P; Perrot L; Pruvost A; Le Grand R; Lagatie O; Vanhooren L; Feyaerts M; van Roey J; Malcolm RK J Antimicrob Chemother; 2014 Sep; 69(9):2477-88. PubMed ID: 24862093 [TBL] [Abstract][Full Text] [Related]
8. A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action. Fetherston SM; Boyd P; McCoy CF; McBride MC; Edwards KL; Ampofo S; Malcolm RK Eur J Pharm Sci; 2013 Feb; 48(3):406-15. PubMed ID: 23266465 [TBL] [Abstract][Full Text] [Related]
9. Physicochemical considerations in the formulation development of silicone elastomer vaginal rings releasing 5-nitroimidazole drugs for the treatment of bacterial vaginosis. Zhao X; Boyd P; Dallal Bashi YH; McCoy CF; Karl Malcolm R Int J Pharm; 2023 Sep; 644():123296. PubMed ID: 37553058 [TBL] [Abstract][Full Text] [Related]
10. Sustained release of proteins from a modified vaginal ring device. Morrow RJ; Woolfson AD; Donnelly L; Curran R; Andrews G; Katinger D; Malcolm RK Eur J Pharm Biopharm; 2011 Jan; 77(1):3-10. PubMed ID: 21055465 [TBL] [Abstract][Full Text] [Related]
11. Packing Polymorphism of Dapivirine and Its Impact on the Performance of a Dapivirine-Releasing Silicone Elastomer Vaginal Ring. McCoy CF; Murphy DJ; Boyd P; Derrick T; Spence P; Devlin B; Malcolm RK J Pharm Sci; 2017 Aug; 106(8):2015-2025. PubMed ID: 28456732 [TBL] [Abstract][Full Text] [Related]
12. Development and pharmacokinetics of a combination vaginal ring for sustained release of dapivirine and the protein microbicide 5P12-RANTES. McBride JW; Malcolm RK; Dias N; Cameron D; Offord RE; Hartley O; Kett VL; Devlin B; Boyd P Int J Pharm; 2019 Jun; 564():207-213. PubMed ID: 30999049 [TBL] [Abstract][Full Text] [Related]
13. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. Malcolm RK; Woolfson AD; Toner CF; Morrow RJ; McCullagh SD J Antimicrob Chemother; 2005 Nov; 56(5):954-6. PubMed ID: 16155060 [TBL] [Abstract][Full Text] [Related]
14. Sustained release of microbicides by newly engineered vaginal rings. Saxena BB; Han YA; Fu D; Rathnam P; Singh M; Laurence J; Lerner S AIDS; 2009 May; 23(8):917-22. PubMed ID: 19381077 [TBL] [Abstract][Full Text] [Related]
15. A Dose Ranging Pharmacokinetic Evaluation of IQP-0528 Released from Intravaginal Rings in Non-Human Primates. Su JT; Teller RS; Srinivasan P; Zhang J; Martin A; Sung S; Smith JM; Kiser PF Pharm Res; 2017 Oct; 34(10):2163-2171. PubMed ID: 28770490 [TBL] [Abstract][Full Text] [Related]
16. In vitro release of nonoxynol-9 from silicone matrix intravaginal rings. Malcolm K; Woolfson D; Russell J; Andrews C J Control Release; 2003 Sep; 91(3):355-64. PubMed ID: 12932713 [TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of drug release from aged prolonged polyethylene oxide tablet matrices: effect of excipient and drug type. Shojaee S; Kaialy W; Cumming KI; Nokhodchi A Pharm Dev Technol; 2016 Mar; 21(2):189-95. PubMed ID: 25410967 [TBL] [Abstract][Full Text] [Related]
19. Controlling the hydration rate of a hydrophilic matrix in the core of an intravaginal ring determines antiretroviral release. Teller RS; Malaspina DC; Rastogi R; Clark JT; Szleifer I; Kiser PF J Control Release; 2016 Feb; 224():176-183. PubMed ID: 26723526 [TBL] [Abstract][Full Text] [Related]
20. Controlled-release vaginal ring drug-delivery systems: a key strategy for the development of effective HIV microbicides. Fetherston SM; Malcolm RK; Woolfson AD Ther Deliv; 2010 Dec; 1(6):785-802. PubMed ID: 22834014 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]